Selective Beta 1-adrenoceptor Blockade Enhances Positive Inotropic Responses to Endogenous Catecholamines Mediated Through Beta 2-adrenoceptors in Human Atrial Myocardium
Overview
Authors
Affiliations
We determined the relative contribution of beta 1- and beta 2-adrenoceptor stimulation to the positive inotropic responses of human atrial myocardium to catecholamines. (-)Norepinephrine produced stimulation predominantly through beta 1-receptors and (-)epinephrine through both beta 1- and beta 2-receptors. However, there were marked differences in the responses of tissues from patients treated with the beta 1-selective antagonist atenolol compared with non-beta-blocker-treated patients; surprisingly, beta 2-mediated responses were enhanced, and beta 1-mediated responses were unaltered. There was an enhanced responsiveness to (-)epinephrine (atenolol treated: -log M EC50, 7.57 +/- 0.07; non-beta-blocker treated: -log M EC50, 6.77 +/- 0.17; p less than 0.001), and the relative importance of beta 2-adrenoceptor stimulation was increased for both (-)norepinephrine and (-)epinephrine. In tissues from atenolol-treated patients, salbutamol, a beta 2-selective partial agonist, had an enhanced potency and a greater intrinsic activity (atenolol treated: -log M EC50, 7.13 +/- 0.09; intrinsic activity, 0.86 +/- 0.04; non-beta-blocker treated: -log M EC50, 5.76 +/- 0.44; intrinsic activity, 0.39 +/- 0.13). We investigated possible mechanisms underlying the enhanced responsiveness to beta 2 stimulation. Determination of beta 2-adrenoceptor affinity for salbutamol showed no change of affinity in atenolol-treated patients. Responses of the tissues to the cyclic AMP analogue dibutyryl cyclic AMP were not different between atenolol-treated and non-beta-blocker-treated patients. The results suggest that chronic blockade of beta 1-adrenoceptors causes enhanced coupling of beta 2-adrenoceptors to adenylate cyclase or to other mechanisms leading to increased contractile force.
Talamonti E, Davegardh J, Kalinovich A, van Beek S, Dehvari N, Halleskog C Mol Metab. 2024; 85:101931.
PMID: 38796310 PMC: 11258667. DOI: 10.1016/j.molmet.2024.101931.
Sonmez M, Goldack S, Nurkkala E, Schulz C, Klampe B, Schulze T Europace. 2024; 26(6).
PMID: 38788213 PMC: 11167676. DOI: 10.1093/europace/euae140.
Pathophysiology of Atrial Fibrillation and Approach to Therapy in Subjects Less than 60 Years Old.
Curcio A, Scalise R, Indolfi C Int J Mol Sci. 2024; 25(2).
PMID: 38255832 PMC: 10815447. DOI: 10.3390/ijms25020758.
Grazette L, Tran J, Zawadzki N, Zawadzki R, McLeod J, Fong M Int J Cardiol Heart Vasc. 2022; 39:100948.
PMID: 35242996 PMC: 8857491. DOI: 10.1016/j.ijcha.2021.100948.
Galindo-Tovar A, Vargas M, Kaumann A Naunyn Schmiedebergs Arch Pharmacol. 2018; 391(6):571-585.
PMID: 29556684 DOI: 10.1007/s00210-018-1480-x.